Form 4: Akebia CCO Nicholas Grund Receives Equity Grant

Akebia Therapeutics' Chief Commercial Officer, Nicholas Grund, was granted 204,000 restricted stock units and 320,000 stock options on January 30, 2026.

Summary

• Nicholas Grund, Chief Commercial Officer of Akebia Therapeutics, Inc. (AKBA), reported the acquisition of equity securities.
• On January 30, 2026, Grund was granted 204,000 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• Following this transaction, Grund beneficially owns 646,579 shares of Common Stock.
• The RSUs will vest in three equal annual installments, with one-third vesting on each of the first, second, and third anniversaries of the grant date, subject to continued service.
• Additionally, Grund was granted 320,000 stock options with an exercise price of $1.41 per share, also at a grant price of $0.00.
• These stock options will vest over four years: 25% on the first anniversary of the grant date, and the remaining 75% in equal quarterly installments thereafter, subject to continued service.
• The stock options have an expiration date of January 30, 2036.
• The grants were made pursuant to Akebia Therapeutics' 2023 Stock Incentive Plan, as amended.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a routine executive compensation event that aligns management's interests with shareholders. It is not a significant market-moving event but reflects standard corporate governance practices.

Positives

• The grant of restricted stock units and stock options aligns the Chief Commercial Officer's long-term incentives with shareholder interests, encouraging sustained performance.
• Equity compensation is a standard practice for retaining and motivating key executives in the biotechnology and pharmaceutical industries.

Negatives

• Potential for future dilution of existing shareholders' equity as the granted 204,000 restricted stock units and 320,000 stock options vest and convert into common stock.

Future Outlook

The equity grants are structured to incentivize the Chief Commercial Officer's continued service and performance over the next three to four years, with vesting schedules extending through January 2029 for RSUs and quarterly thereafter for options, and options expiring in January 2036.

Industry Context

StockSavvy.ai notes that equity grants, including restricted stock units and stock options, are a common and widely accepted form of executive compensation within the biotechnology and pharmaceutical sectors. These grants are designed to align the interests of executives with those of shareholders by tying a significant portion of their compensation to the company's stock performance and long-term success.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages across the biotechnology industry, similar to practices at companies like Biogen, Vertex Pharmaceuticals, and Moderna.
• The vesting schedules (three years for RSUs, four years for options with a one-year cliff) are typical for executive equity awards, aiming to promote long-term retention and performance.
• The exercise price of $1.41 for stock options is common, reflecting the market price at the time of grant, ensuring that the options gain value only if the stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution from the vesting of 204,000 restricted stock units and 320,000 stock options, balanced by increased alignment of executive incentives with shareholder value creation.
• Employees: The grant represents a component of executive compensation, potentially impacting morale and retention for the Chief Commercial Officer.

Next Steps

• The restricted stock units will vest in one-third increments on the first, second, and third anniversaries of the grant date (January 30, 2027, 2028, and 2029).
• The stock options will vest 25% on the first anniversary of the grant date (January 30, 2027), with the remaining 75% vesting in equal quarterly installments thereafter.
• The Chief Commercial Officer's continued service with the Issuer is required for vesting on each respective date.

Key Dates

Keywords

Akebia Therapeutics, AKBA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Biotechnology